Harmony Biosciences Holdings (HRMY) — Cash Flow Reinvestment Rate
Harmony Biosciences Holdings (HRMY) has a Cash Flow Reinvestment Rate of 1.42x as of June 2026, reinvesting $131.50 Million (capex $0.00 plus investments $-131.50 Million) from operating cash flow of $92.43 Million. See HRMY FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Harmony Biosciences Holdings Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for Harmony Biosciences Holdings across 5 annual periods. For the full cash flow conversion analysis, see HRMY operating cash flow.
Annual Cash Flow Reinvestment Rate for Harmony Biosciences Holdings (2021–2025)
Year-by-year capital reinvestment analysis for Harmony Biosciences Holdings. See how financially flexible is Harmony Biosciences Holdings to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | $5.40 Million | $348.20 Million | $310.00K | ▼ -95.0% |
| 2024 | 0.31x | $68.64 Million | $219.82 Million | $1.15 Million | ▲ +19.0% |
| 2023 | 0.26x | $57.58 Million | $219.39 Million | $312.00K | ▼ -73.3% |
| 2022 | 0.98x | $142.00 Million | $144.47 Million | $172.00K | ▼ -3.7% |
| 2021 | 1.02x | $100.60 Million | $98.56 Million | $298.00K | — |